Mersana Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell MRSN and other ETFs, options, and stocks.About MRSN
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592.
CEOMartin H. Huber
CEOMartin H. Huber
Employees102
Employees102
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2001
Founded2001
Employees102
Employees102
MRSN Key Statistics
Market cap42.07M
Market cap42.07M
Price-Earnings ratio-0.54
Price-Earnings ratio-0.54
Dividend yield—
Dividend yield—
Average volume37.79K
Average volume37.79K
High today$8.43
High today$8.43
Low today$7.54
Low today$7.54
Open price$8.00
Open price$8.00
Volume33.95K
Volume33.95K
52 Week high$70.75
52 Week high$70.75
52 Week low$5.21
52 Week low$5.21
Stock Snapshot
With a market cap of 42.07M, Mersana Therapeutics(MRSN) trades at $8.41. The stock has a price-to-earnings ratio of -0.54.
On 2025-11-07, Mersana Therapeutics(MRSN) stock traded between a low of $7.54 and a high of $8.43. Shares are currently priced at $8.41, which is +11.5% above the low and -0.2% below the high.
Mersana Therapeutics(MRSN) shares are trading with a volume of 33.95K, against a daily average of 37.79K.
During the past year, Mersana Therapeutics(MRSN) stock moved between $5.21 at its lowest and $70.75 at its peak.
During the past year, Mersana Therapeutics(MRSN) stock moved between $5.21 at its lowest and $70.75 at its peak.
Analyst ratings
89%
of 9 ratingsBuy
88.9%
Hold
11.1%
Sell
0%
People also own
Based on the portfolios of people who own MRSN. This list is generated using Robinhood data, and it’s not a recommendation.